Alzheimer’s disease: the new promise

J Clin Invest. 2012 Apr;122(4):1191. doi: 10.1172/jci62745.

Abstract

Clinical vignette: A 59-year-old aeronautical engineer is referred to you for evaluation because of increasing difficulty with job performance over the last several years. Difficulty managing home finances, getting lost driving, and forgetting appointments have become common. Previously outgoing, he is now depressed and irritable. After appropriate neurologic assessment, including brain imaging and metabolic studies, you make the diagnosis of Alzheimer’s dementia and are asked by the patient’s family what treatment is available.

Publication types

  • Comment

MeSH terms

  • Alzheimer Disease / metabolism*
  • Amyloid beta-Peptides / toxicity*
  • Animals
  • Brain / metabolism*
  • Cognition Disorders / etiology*
  • Exenatide
  • Female
  • Hippocampus / drug effects*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / physiology*
  • Insulin Receptor Substrate Proteins / metabolism*
  • Insulin Receptor Substrate Proteins / physiology*
  • Insulin Resistance*
  • Insulin-Like Growth Factor I / pharmacology*
  • Male
  • Peptides / therapeutic use*
  • Venoms / therapeutic use*

Substances

  • Amyloid beta-Peptides
  • Hypoglycemic Agents
  • IRS1 protein, human
  • Insulin
  • Insulin Receptor Substrate Proteins
  • Peptides
  • Venoms
  • Insulin-Like Growth Factor I
  • Exenatide